Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Hemochromatosis (Iron Overload) Disease Treatment Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The hemochromatosis (iron overload) disease treatment market size has experienced consistent expansion over recent years. It is anticipated to rise from $28.62 billion in 2025 to $29.56 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 3.3%. The market’s past growth was driven by enhanced recognition of hereditary iron overload, a greater availability of diagnostic testing, increased adoption of phlebotomy as standard care, heightened clinical awareness, and the presence of chelation therapies.
The hemochromatosis (iron overload) disease treatment market size is anticipated to experience consistent expansion over the upcoming years. It is projected to reach $34.8 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.2%. This projected growth during the forecast period is driven by factors such as the greater acceptance of personalized treatment approaches, an increasing need for non-invasive monitoring solutions, the broadening availability of genetic counseling services, a heightened emphasis on early intervention, and more extensive research into novel therapeutic options. Key trends anticipated during this period encompass a stronger focus on early genetic screening, an increase in the implementation of therapeutic phlebotomy protocols, wider application of iron chelation therapies, the expansion of initiatives to raise disease awareness programs, and an enhanced commitment to long-term disease management.
Get A Free Sample Report With In-Depth Market Insights:
Hemochromatosis (Iron Overload) Disease Treatment Market Expansion Drivers: What’s Shaping Future Growth?
The rising prevalence of stressful lifestyles is projected to stimulate growth in the hemochromatosis (iron overload) disease treatment market in the coming years. Stressful living significantly impacts a person’s physical and mental health, and extended periods of high stress can lead to numerous health problems, including hemochromatosis (iron overload) disease. The treatment for hemochromatosis, a condition characterized by an excess of iron in the body, not only addresses the physical symptoms but also plays a crucial role in mitigating the emotional and psychological stress that frequently accompanies managing a chronic illness. For instance, in November 2025, according to the American Psychiatric Association, a US-based professional organization of psychiatrists and trainee psychiatrists, 41% among U.S. adults stated they anticipate more stress related to the holidays this year than last year, representing a significant increase over 2024 (28%) and 2023 (29%). Therefore, the increasingly stressful lifestyle is a primary driver for the hemochromatosis (iron overload) disease treatment market.
Hemochromatosis (Iron Overload) Disease Treatment Market Segmentation And Category Overview
The hemochromatosis (iron overload) disease treatment market covered in this report is segmented –
1) By Type: Hereditary Hemochromatosis, Acquired Hemochromatosis
2) By Treatment: Therapeutic Phlebotomy, Iron Chelation Therapy, Other Treatments
3) By End-Users: Hospitals, Surgical Centers, Other End-Users
Subsegments:
1) By Hereditary Hemochromatosis: Genetic Counseling, Phlebotomy, Chelation Therapy
2) By Acquired Hemochromatosis: Treatment Of Underlying Conditions, Phlebotomy, Chelation Therapy
Hemochromatosis (Iron Overload) Disease Treatment Market Industry Trends Fueling Future Revenue Growth
Major companies engaged in the hemochromatosis (iron overload) disease treatment market obtain approvals for drugs like deferiprone, intended for patients suffering from transfusional iron overload to assist in reducing excess iron levels in the body and preventing complications associated with iron accumulation, such as organ damage. Deferiprone is a medication used to manage iron overload in individuals who have received multiple blood transfusions, a common occurrence in conditions including thalassemia, sickle cell anemia, or other chronic anemias. For example, in March 2023, Chiesi Global Rare Diseases Inc, a US-based business unit, disclosed the approval of FERRIPROX MR (deferiprone) extended-release tablets in Canada. FERRIPROX MR is indicated for addressing transfusional iron overload in patients with thalassemia syndromes when current chelation therapy proves inadequate, and also for patients with sickle cell disease (SCD) or other types of anemia. Deferiprone operates as an orally active iron-chelating agent that effectively lowers iron concentration within the body by penetrating cell membranes and binding to surplus iron, thus facilitating its removal from organs and tissues.
Hemochromatosis (Iron Overload) Disease Treatment Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the hemochromatosis (iron overload) disease treatment market are Pfizer Inc., AbbVie Inc., Novartis AG, Merck KGaA, Sanofi SA, Takeda Pharmaceutical Company Limited, Bayer AG, GlaxoSmithKline plc, Roche Holding AG, Abbott Laboratories, Fresenius Kabi AG, Apotex Inc., Teva Pharmaceutical Industries Ltd., Recordati S.p.A., Chiesi Farmaceutici S.p.A., Ionis Pharmaceuticals Inc., Silence Therapeutics, DisperSol Technologies LLC., Hinoman Ltd., Pharmacosmos A/S
View The Full Hemochromatosis (Iron Overload) Disease Treatment Market Report:
Hemochromatosis (Iron Overload) Disease Treatment Market Top Region By Revenue And Market Share
North America was the largest region in the hemochromatosis (Iron Overload) disease treatment market in 2025. The regions covered in the hemochromatosis (iron overload) disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









